LONDON, Apr 20 (APM) - The European Commission has quashed the UK's hopes of keeping the European Medicines Agency (EMA) in London after Brexit.
On April 16 in the Financial Times, Brexit secretary David Davis had said he did not accept that two key authorities - the EMA and European Banking Authority - would have to move out of the UK (APMMA 52697).
A Brexit department spokesperson added that relocation decisions were all subject to exit negotiations.
However, on Wednesday European Commission spokesperson Margaritis Schinas said this will not be the case.
In a Commission video posted on Twitter, he said: "The European Union agencies must be based in the territory of the European Union.
"The decision to relocate the European Medicines Agency and the European Banking Authority is a decision for the 27 member states to take, it is not part of the Brexit negotiations. It's rather a consequence of Brexit.
"The United Kingdom is leaving the European Union and it will have no say in the location of EU agencies."
Roughly 1,000 staff will have to move from London's Canary Wharf as part of the agencies' relocation, according to the Financial Times.
Since the Brexit vote, 21 EU countries have staked an interest in hosting the EMA and its roughly 900-strong workforce, including Germany (APMMA 52651), Spain (APMMA 52344), Denmark (APME 51715), the Netherlands (APMMA 51352) and Sweden (APMMA 50829).
/nm/clg
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
